Australian Authorities.

Australian Authorities have approved Larch arabinogalactan from Lonza, Basel, Switzerland, as a therapeutically active ingredient for oral use. Three requirements were met to garner the approval: the ingredient arabinogalactan (Larix) is derived from Larix larcinia or Larix occidentalis; the concentration of polysaccharides in the ingredient is greater than or equal to 85% and the maximum recommended daily dose of the ingredient does not exceed 15 grams. In Australia, Larch arabinogalactan had previously been approved as a food additive only.